PROCESS FOR APPLYING A CREAM COMPOSED OF BOTULINUM TOXIN POTENTIALIZERS AND MUSCLE RELAXANTS, IN AN ACTIVE INGREDIENT WITH GOOD SKIN PERMEATION TO INCREASE THE EFFECTIVENESS OF TREATMENTS
A cream combining ARGIRELINE and Matrixil 3000 enhances botulinum toxin efficacy by blocking acetylcholine release, addressing suboptimal formulations and resistance issues, achieving faster and longer-lasting results.
Patent Information
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Filing Date
- 2024-12-26
- Publication Date
- 2026-07-07
AI Technical Summary
Current formulations for botulinum toxin applications lack a combination of toxin action enhancers and muscle relaxants, resulting in suboptimal efficacy and limited effectiveness, especially in patients with partial resistance, and there is a need for a more effective delivery vehicle to enhance the action and duration of botulinum toxin treatments.
A cream formulation combining ARGIRELINE, magnesium sulfate, SNAP 8, zinc citrate, cinchona succiruba bark extract, neomycin, and bacitracin, along with Matrixil 3000, which includes glycerin, aqua, butylene glycol, carbomer, polysorbate 20, palmitoyl tripeptide-1, and palmitoyl tetrapeptide-7, is applied to toxin injection sites for 7-14 days to enhance skin permeation and muscle relaxation, blocking acetylcholine release.
The cream provides faster and longer-lasting results, visible within 3 days, and is effective in patients resistant to botulinum toxin, with visible differences when applied to one side of the face compared to the other, offering excellent cost and safety for short-term use.